^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GC022F

    i
    Other names: GC022F, CD19 and CD22 targeted CAR-T cells, GC022
    Associations

    News

    Trials
    Company:
    AstraZeneca
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over3years
    Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=18, Not yet recruiting, He Huang
    Clinical • New P1/2 trial
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    GC022F